IZEA Reports Q3 2026 Revenue of $6.2 million, 94% increase in Managed Services Bookings

IZEA Worldwide, Inc. (IZEA) filed an SEC Form 8-K — Results of Operations and Financial Condition. IZEA Reports Q3 2026 Revenue of $6.2 million, 94% increase in Managed Services Bookings Enterprise Relationships Remain Strong Amid Market Uncertainties ORLANDO, Fla. ( November 12, 2026 ) - IZEA Worldwide, Inc. (NASDAQ: IZEA), a leading influencer marketing company that makes Cr

Original reporting
Published Nov 12, 2026, 9:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 9:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$IZEA
Neutral
high confidence
Mentioned
$IZEA
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$IZEANeutralMed
01

Why it matters

The earnings release provides fresh data on revenue trends, booking momentum, and cash resources, shaping short‑term price expectations.

02

Market read

First‑report earnings for a micro‑cap creator‑marketing firm; modest trading relevance with potential upside from strong bookings.

03

What to watch

Strong cash position and no debt give flexibility for acquisitions that could accelerate growth.

Relevance 7/10Novelty 7/10Timing: after-hours today

Background

The filing is an SEC Form 8‑K Item 2.02 reporting Q3 2026 results and forward guidance.

Company-level read

Ticker impact

$IZEANeutralHigh confidence
Context

Q3 2026 earnings disclosed a 23% revenue decline to $6.2M but a 94% jump in Managed Services bookings to $7.0M and provided Q4 revenue guidance of $7.5M‑$8.1M.

Expected impact

potential modest upside as the market prices in strong bookings and cash balance despite revenue decline

Evidence & confidence

First‑report 8‑K earnings release; revenue drop is a negative, but 94% booking growth and a cash pile of $46.4M with no debt provide upside catalysts.

Market effects

Highlights growing demand for creator‑economy services, may benefit peers in influencer marketing.

U.S. micro‑cap tech sector sees mixed reaction; no broader regional effect.

Limited to niche creator‑marketing space; unlikely to move broader indices.

Counterpoint

Revenue decline could signal deeper market weakness; investors may short despite booking growth.

Key entities

  • Patrick Venetucci

    CEO of IZEA, quoted on results and outlook.

Related articles

$IZEAMedAI 8/10

IZEA (IZEA) Q2 2026 Earnings Call Transcript

IZEA reported Q2 2026 revenue of $5.8M, down 36% YoY, and a net loss of $0.7M, as it shifts to larger enterprise accounts. Managed services bookings fell 19% YoY, while SaaS revenue declined 32%. The company has $46.6M in cash and no long-term debt. Management highlighted new enterprise wins and an active M&A pipeline, but noted macroeconomic uncertainty.

$IZEAMed

IZEA Reports Q2 2026 Revenue of $5.8 million, Advances Enterprise-Focused Growth Strategy

IZEA Worldwide, Inc. (IZEA) filed an SEC Form 8-K — Results of Operations and Financial Condition. IZEA Reports Q2 2026 Revenue of $5.8 million, Advances Enterprise-Focused Growth Strategy Enterprise Relationships Remain Strong Amid Market Uncertainties ORLANDO, Fla. ( August 11, 2026 ) - IZEA Worldwide, Inc. (NASDAQ: IZEA), a leading influencer marketing company that makes Cr

$NOKMed

LightCounting:: November 2026 Nokia SReXperts

Nokia hosted its SReXperts/Wavelengths conference in November 2026, focusing on AI's impact on connectivity and its solutions for customers. The company reported strong Q3 2026 earnings, with AI & Cloud sales doubling year-over-year and $1.7 billion in new orders. Nokia expects 25-30% growth in its Optical and IP Networks businesses in 2027. The company aims to help telecom operators adapt to AI-driven changes and capitalize on new opportunities.

$IBRXLow

IBRX Stock Eyes Best Year Ever: Founder Teases 12 Months Of ‘Stealth’ NantWorks Reveals — Cancer Tech, AI Chips And Satellites

ImmunityBio (IBRX) reported a 53% increase in Q3 net product revenue to $48.7M, with 92% growth for the first nine months. The company is testing its drug Anktiva for sepsis and aims to expand FDA approval for bladder cancer. NantWorks, led by Patrick Soon-Shiong, plans a blockchain-based exchange for tokenized securities. IBRX stock has risen 195% over the past year, with bullish retail sentiment on Stocktwits.